Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.780 +0.060 (+3.49%)
Streaming Delayed Price Updated: 2:43 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock ↗
 
Via Benzinga
News headline image
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 10, 2025 ↗
 
Via Benzinga
News headline image
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Forecasting The Future: 6 Analyst Projections For Lineage Cell Therapeutics ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Lineage Cell Therapeutics In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Lineage Cell Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Issues Letter to Stockholders
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 14, 2024 ↗
 
Via Benzinga
News headline image
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage to Present at 2024 BIO International Convention
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
LCTX Stock Earnings: Lineage Cell Therapeutics Meets EPS, Beats Revenue for Q1 2024 ↗
LCTX stock results show that Lineage Cell Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.